Evidence map›Paper›PMID 27932443›Full record

ArticleEMBO molecular medicine2017

PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy.

Abul Azad, Su Yin Lim, Zenobia D'Costa, Keaton Jones, Angela Diana, Owen J Sansom, Philipp Kruger, Stanley Liu, W Gillies McKenna, Omer Dushek and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EMBO molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 140 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
140citing papers in PubMed, 3 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

140 citing papers in PubMed, 3 syntheses or guidelines pooled it, 223 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis.International journal of molecular sciences · 2021
    Pooled it
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

80 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Abul AzadDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Su Yin LimDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Zenobia D'CostaDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Keaton JonesDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Angela DianaDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Owen J SansomCRUK Beatson Cancer Institute, University of Glasgow, Glasgow, UK.ORCID 0000-0001-9540-3010
Philipp KrugerSir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Stanley LiuDepartment of Radiation Oncology, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
W Gillies McKennaDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Omer DushekSir William Dunn School of Pathology, University of Oxford, Oxford, UK.ORCID 0000-0001-5847-5226
Ruth J MuschelDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK.
Emmanouil FokasDepartment of Oncology, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford, UK emmanouil.fokas@oncology.ox.ac.uk.ORCID 0000-0003-1601-6165
University of Oxford · GBCancer Research UK Scotland Institute · GBSunnybrook Health Science Centre · CA

Funding

Cancer Research UK 16466Cancer Research UK 20407Cancer Research UK 21139Medical Research Council MC_PC_12004Medical Research Council MC_UU_00001/5Wellcome Trust 098363
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is considered a non-immunogenic tumor, and immune checkpoint inhibitor monotherapy lacks efficacy in this disease. Radiotherapy (RT) can stimulate the immune system. Here, we show that treatment of KPC and Pan02 murine PDAC cells with RT and gemcitabine upregulated PD-L1 expression in a JAK/Stat1-dependent manner. In vitro, PD-L1 inhibition did not alter radio- and chemosensitivity. In vivo, addition of anti-PD-L1 to high (12, 5 × 3, 20 Gy) but not low (6, 5 × 2 Gy) RT doses significantly improved tumor response in KPC and Pan02 allografts. Radiosensitization after PD-L1 blockade was associated with reduced CD11b

Indexed as

AdenocarcinomaAnimalsB7-H1 AntigenCarcinoma, Pancreatic DuctalCD8-Positive T-LymphocytesDeoxycytidineDisease Models, AnimalGemcitabineMiceModels, TheoreticalRadiation-Sensitizing AgentsTreatment OutcomeB7-H1 AntigenCd274 protein, mouseDeoxycytidineGemcitabineRadiation-Sensitizing Agentsliver metastasesmathematical modelingpancreatic cancerPD‐L1 immune checkpointradiosensitization

Identifiers

PMID27932443
PMCPMC5286375
OpenAlexW2560628113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.